secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001437749-23-014610
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica files clinical hold response; Q1 cash $28.7M; Phase 1C confirms DM199 dose safety
--------------------------------------------------------------------------------

- Company will file complete clinical hold response to FDA this week for ReMEDy2 AIS trial; in-use study supports dose revision to 0.5 µg/kg IV.
- Phase 1C SAD study in healthy volunteers affirms revised DM199 IV dose is well-tolerated and achieves therapeutic blood levels.
- Cash, cash equivalents and investments $28.7M as of March 31, 2023; working capital $26.9M; cash runway into Q4 2024.
- R&D expenses $3.6M in Q1 2023, up 80% YoY, driven by clinical hold studies and team expansion; G&A $1.9M, up 19%.
- Post-quarter $0.75M private investment from newly appointed Chief Business Officer; net cash used in ops $5.1M in Q1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774923014610/0001437749-23-014610-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774923014610/dmtp20230512_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-014610

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer